Eli Lilly May Have Just Found a New $23 Billion Market for Its GLP-1 Pill

Eli Lilly (NYSE:LLY) just gave its newest drug a second act. Foundayo, which CEO David Ricks calls “the only approved GLP-1 pill that can be taken any time of day, without food and water restrictions,” significantly improved obstructive sleep apnea severity in the Phase 3 ATTAIN-OSA trial, with a U.S. FDA submission planned by the end of 2026. Foundayo sales already rose from $98 million in Q2 to $184 million in Q3.

Shares are up 28.29% year-to-date and 47.28% over the past year. Ricks put it simply: “We are in the middle of the largest new category expansion in the history of the pharmaceutical industry, and Lilly is leading that.” Lilly needs a 31% gain to hit $1,800 per share in 2027.

Wall Street’s Average Target Lags Its Most Bullish Call

The consensus target of $1,453.40 implies only about 6% upside from $1,372. The high end is moving, though. Jefferies raised its target to $1,700 from $1,610, a Street-high, citing larger-than-expected international obesity market potential.

Analysts expect 2027 EPS of $50.1525, up from $35.3522 in 2026, about 42% growth. Ninety days ago, that 2027 figure was $45.0802.

Can Eli Lilly Really Hit $1,800? Here’s the Math

At $1,372, Lilly trades at 27x 2027 earnings. At $1,800, that multiple would be 36x, above the S&P 500’s 21-23x. That premium is justified for earnings growing near 42%, and Lilly has beaten estimates for five consecutive quarters, including Q3 EPS of $7.48 versus $6.67 expected.

What Could Push Eli Lilly to $1,800?

• Foundayo in diabetes: Lilly expects regulatory action in type 2 diabetes in Q4, and Ricks noted “roughly half the volume of GLP-1s is in diabetes.”
• Global rollout: Foundayo is under review in more than 40 additional countries, with a broad launch targeted for 2027.
• Retatrutide: A BLA submission is planned for Q1 2027 after it delivered 20% to 21% weight loss versus 9.4% for semaglutide.
• Medicare access: The Bridge Program opened obesity coverage to approximately 20 million seniors.
• Untapped demand: The CFO said Lilly reaches “one out of 10 patients” in the U.S.

Eli Lilly Has Topped 31% in Each of the Past Five Years

The 31% gain needed for $1,800 is routine by recent standards. Lilly returned 66.1% in 2021, 34.2% in 2022, 60.9% in 2023, 33.3% in 2024 and 40.2% in 2025. At a $1.22 trillion market cap, each gain demands more absolute dollars, but the run shows consistent compounding.

$1,800 Is a Stretch, but the Blueprint Is Clear

Reaching $1,800 requires a 31% gain in 2027. Rising estimates, a beat run and new Foundayo indications support the case. Hurdles include a 15% decline in realized prices and approximately $2 billion of 2026 one-time items that won’t repeat. Lilly will issue 2027 guidance in January, a near-term test for the thesis. Returns at this level shouldn’t be expected every year, but we’ve outlined the plan for how Eli Lilly could see outsized returns in 2027.